Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Discovering drug resistance mechanisms in multiple myeloma & identifying novel treatment targets

Yael Cohen • 27 Aug 2022
IMS 2022
Multiple Myeloma Carfilzomib

Yael Cohen, MD, Tel-Aviv Sourasky Medical center, Tel-Aviv, Israel, outlines the different mechanisms of drug resistance in multiple myeloma, highlighting the possibility of finding new treatment targets using single-cell RNA sequencing (scRNA-seq). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yael Cohen

5:54
RedirecTT-1 results: teclistamab + talquetamab in R/R multiple myeloma
Yael Cohen • 4 Jun 2023
2:37
Real-world safety and efficacy of belantamab mafodotin in R/R multiple myeloma
Yael Cohen • 27 Aug 2022
3:03
The use of single-cell RNA sequencing to identify mechanisms of drug resistance in multiple myeloma
Yael Cohen • 27 Aug 2022
1:53
Factors to consider for the optimal management of relapse in multiple myeloma
Yael Cohen • 27 Jul 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals